Cyclooxygenase-2 expression is associated with poor overall survival of patients with gastric cancer: a meta-analysis

Dig Dis Sci. 2014 Feb;59(2):436-45. doi: 10.1007/s10620-013-2917-1. Epub 2013 Nov 1.

Abstract

Background: Cyclooxygenase-2 (COX-2) is believed to be involved in gastric carcinogenesis. However, it is still controversial whether COX-2 expression can be regarded as a prognostic factor for gastric cancer patients.

Aim: To obtain a more accurate relationship between COX-2 overexpression and prognosis in gastric cancer by meta-analysis.

Method: Relevant articles published up to May 2013 were searched by use of several keywords in electronic databases. Separate hazard ratio (HR) estimates and 95 % confidence intervals (95 % CI) for COX-2 overexpression and overall survival (OS) and disease-free survival (DFS) with gastric cancer were extracted. Combined HR with 95 % CI was calculated by use of Stata11.0 software to estimate the size of the effect. Publication bias testing and sensitivity analysis were also performed.

Results: A total of 27 studies which included 3,891 gastric cancer patients were combined in the final analysis. Combined results suggested that COX-2 overexpression was associated with an unfavorable OS (HR 1.58, 95 % CI 1.36-1.84) but not DFS (HR 1.15, 95 % CI 0.93-1.43) among patients with gastric cancer. Publication bias was absent. Sensitivity analysis suggested that the results of this meta-analysis were robust.

Conclusions: The results of this meta-analysis suggest that high COX-2 expression may be an independent risk factor for poor OS of patients with gastric cancer. More large prospective studies are now needed to further clarify the prognostic value of COX-2 expression for DFS in gastric cancer.

Publication types

  • Meta-Analysis
  • Review

MeSH terms

  • Biomarkers, Tumor / analysis*
  • Chi-Square Distribution
  • Cyclooxygenase 2 / analysis*
  • Disease-Free Survival
  • Humans
  • Kaplan-Meier Estimate
  • Linear Models
  • Multivariate Analysis
  • Risk Factors
  • Stomach Neoplasms / enzymology*
  • Stomach Neoplasms / mortality*
  • Time Factors
  • Up-Regulation

Substances

  • Biomarkers, Tumor
  • Cyclooxygenase 2
  • PTGS2 protein, human